Director Medical Affairs
Alexion
Director Medical Affairs
Alexion
Global biopharmaceuticals focusing on rare diseases
When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life changing medicines. In-person working gives us the platform to connect, work at pace and challenge perceptions. That’s why we work, on average, a minimum of three days per week from the office. But that doesn’t mean we’re not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.
This is a 12-month contract
Provide scientific and medical leadership for the Canadian Neurology portfolio and lead, coach and develop the Medical Affairs team. Translate the Global Medical Affairs Plan into locally relevant strategies that address patient needs, clinical practice, healthcare-system priorities and access. Working across functions, advance evidence-based care, support health-system transformation and improve patient outcomes throughout the product lifecycle—from development and launch to indication expansion, post-launch optimisation and loss-of-exclusivity planning.
Join a collaborative, diverse culture that values innovation and offers the opportunity to make a meaningful difference in rare disease patients’ lives. Our hybrid approach supports in-person collaboration, with an expectation of working from the office, on average, a minimum of three days per week, balanced with individual flexibility.
Ready to lead and inspire? Apply now to join Alexion, AstraZeneca Rare Disease.
#LI-Hybrid
We are using AI as part of the recruitment process.
This advertisement relates to a current vacancy.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion